公开(公告)号：US20150239912A1

公开(公告)日：2015-08-27

申请号：US14631712

申请日：2015-02-25

Applicant: Infinity Pharmaceuticals, Inc.

Inventor： Brian C. AUSTAD ,  Louis GRENIER ,  Michael J. GROGAN ,  Tao LIU ,  Priscilla L. WHITE ,  Theodore A. MARTINOT ,  Lin-Chen YU

IPC: C07F5/05 ,  C07F5/02

CPC classification number: C07F5/05 ,  C07B2200/13 ,  C07F5/025

Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.

Abstract translation: 本发明提供脂肪酸酰胺水解酶抑制剂，其固体形式，其组合物及其制备和使用方法。

公开(公告)号：US20150368278A1

公开(公告)日：2015-12-24

申请号：US14599192

申请日：2015-01-16

Applicant: INFINITY PHARMACEUTICALS, INC.

Inventor： Mark L. BEHNKE ,  Alfredo C. CASTRO ,  Catherine A. EVANS ,  Louis GRENIER ,  Michael J. GROGAN ,  Tao LIU ,  Daniel A. SNYDER ,  Thomas T. TIBBITTS

IPC: C07F5/02

CPC classification number: C07F5/025 ,  A61K31/69 ,  C07F5/02

Abstract: The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

Abstract translation: 本发明提供了由式（I），（II），（III），（IV），（V）或（VI）或其子类中的任何一种包含的化合物及其药学上可接受的组合物。 本发明还提供了通过施用治疗有效量的化合物或组合物来治疗FAAH介导的疾病，病症或病症的方法，所述化合物或组合物包含式（I），（II），（III），（IV）， （Ⅴ）或（Ⅵ）或其子代的药物给予有需要的患者。 另外，本发明提供了通过施用治疗有效量的包含式（I），（II），（III），（IV），（V）或（（IV））的化合物的化合物或组合物来抑制FAAH的方法， VI）或其子集合。

公开(公告)号：US20160024051A1

公开(公告)日：2016-01-28

申请号：US14776604

申请日：2014-03-13

Applicant: INFINITY PHARMACEUTICALS, INC.

Inventor： Daniel G. GENOV ,  Louis GRENIER ,  Andrew B. HAGUE ,  Alexander Redvers EBERLIN ,  Ludovic Sylvain Marc RENOU ,  Susana DEL RIO GANCEDO

IPC: C07D401/14 ,  C07C309/05 ,  C07C57/145

CPC classification number: C07D401/14 ,  A61K31/506 ,  C07B2200/13 ,  C07C57/145 ,  C07C309/05 ,  C07D401/12

Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, solid forms thereof, and pharmaceutical compositions thereof.

Abstract translation: 本文描述了调节激酶活性（包括PI3激酶活性）的化合物的固体形式，以及化合物，药物组合物和治疗与激酶活性（包括PI3激酶活性）相关的疾病和病症的方法。 本文还提供了制备化合物，其固体形式及其药物组合物的方法。

公开(公告)号：US20130059819A1

公开(公告)日：2013-03-07

申请号：US13662268

申请日：2012-10-26

Applicant: INFINITY PHARMACEUTICALS, INC.

Inventor： Julian ADAMS ,  Mark L. BEHNKE ,  Alfredo C. CASTRO ,  Catherine A. EVANS ,  Louis GRENIER ,  Michael J. GROGAN ,  Tao LIU ,  Daniel A. SNYDER ,  Thomas T. TIBBITTS

IPC: A61K31/69 ,  A61P25/00 ,  A61P25/06 ,  C07F5/02

CPC classification number: C07F5/025 ,  A61K31/69 ,  C07F5/05

Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.

公开(公告)号：US20150099738A1

公开(公告)日：2015-04-09

申请号：US14320435

申请日：2014-06-30

Applicant: INFINITY PHARMACEUTICALS, INC.

Inventor： Mark L. BEHNKE ,  Alfredo C. CASTRO ,  Lawrence K. CHAN ,  Catherine A. EVANS ,  Louis GRENIER ,  Michael J. GROGAN ,  Yves LEBLANC ,  Tao LIU ,  Stephane PELUSO ,  Daniel A. SNYDER ,  Thomas T. TIBBITTS

IPC: C07D498/10 ,  C07D261/20

CPC classification number: C07D498/10 ,  A61K31/42 ,  A61K31/438 ,  A61K31/55 ,  C07D261/20 ,  C07D498/04

Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

Abstract translation: 本发明提供式（I）的异恶唑啉FAAH抑制剂或其药学上可接受的形式，其中G，Ra，Rb，Rc和Rd各自如本文所定义。 本发明还提供包含式（I）化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法，包括向有需要的受试者施用治疗有效量的式（I）化合物或其药学上可接受的形式。

公开(公告)号：US20140275135A1

公开(公告)日：2014-09-18

申请号：US14209842

申请日：2014-03-13

Applicant: Infinity Pharmaceuticals, Inc.

Inventor： Daniel G. GENOV ,  Louis GRENIER ,  Andrew B. HAGUE ,  Alexander Redvers EBERLIN ,  Ludovic Sylvain Marc RENOU ,  Susana DEL RIO GANCEDO

IPC: C07D401/14 ,  G01N31/16

CPC classification number: C07D401/14 ,  A61K31/4725

Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, solid forms thereof, and pharmaceutical compositions thereof.

Abstract translation: 本文描述了调节激酶活性（包括PI3激酶活性）的化合物的固体形式，以及化合物，药物组合物和治疗与激酶活性（包括PI3激酶活性）相关的疾病和病症的方法。 本文还提供了制备化合物，其固体形式及其药物组合物的方法。